Integrated analysis of next generation sequencing minimal residual disease (MRD) and PET scan in transplant eligible myeloma patients.

Fonseca, Rodrigo; Arribas, Mariano; Wiedmeier-Nutor, Julia E.; Kusne, Yael N.; González Vélez, Miguel; Kosiorek, Heidi E.; Butterfield, Richard J.; Kirsch, Ilan R.; Mikhael, Joseph R.; Stewart, A. Keith; Reeder, Craig; Larsen, Jeremy; Bergsagel, P. Leif; Fonseca, Rafael

Minimal residual disease (MRD) assays allow response assessment in patients with multiple myeloma (MM), and negativity is associated with improved survival outcomes. The role of highly sensitive next generation sequencing (NGS) MRD in combination with functional imaging remains to be validated. We performed a retrospective analysis on MM patients who underwent frontline autologous stem cell transplant (ASCT). Patients were evaluated at day 100 post-ASCT with NGS-MRD and positron emission tomography (PET-CT). Patients with ≥ 2 MRD measurements were included in a secondary analysis for sequential measurements. 186 patients were included. At day 100, 45 (24.2%) patients achieved MRD negativity at a sensitivity threshold of 10−6. MRD negativity was the most predictive factor for longer time to next treatment (TTNT). Negativity rates did not differ according to MM subtype, R-ISS Stage nor cytogenetic risk. PET-CT and MRD had poor agreement, with high rates of PET-CT negativity in MRD-positive patients. Patients with sustained MRD negativity had longer TTNT, regardless of baseline risk characteristics. Our results show that the ability to measure deeper and sustainable responses distinguishes patients with better outcomes. Achieving MRD negativity was the strongest prognostic marker and could help guide therapy-related decisions and serve as a response marker for clinical trials.

NUCLEOTIDE sequencing; POSITRON emission tomography; POSITRON emission tomography computed tomography; STEM cell transplantation; MULTIPLE myeloma

Blood Cancer Journal, 2023, Vol 13, Issue 1, p1

2044-5385

Academic Journal

10.1038/s41408-023-00794-x